Close Menu

 NEW YORK (360Dx) – Recent changes in professional guidelines regarding the use of cell-free DNA-based noninvasive prenatal screening for fetal aneuploidies are starting to have an effect in several large reference labs, which are seeing significant growth in the use of NIPT for screening average-risk patients.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.